Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Rhea-AI Summary

Compugen (NASDAQ: CGEN) will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.

Telephone access is available in the U.S. and internationally, and a replay will be posted on the company website after the live webcast.

News Market Reaction – CGEN

+1.82%

+1.82% Session close to close

In the Feb 17 session, CGEN gained 1.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Compugen’s Q4 and full-year 2025 results and conference call, signaling ...

Analysis

This announcement schedules Compugen’s Q4 and full-year 2025 results and conference call, signaling the next checkpoint after Q3 cash of $86.1M, runway into Q3 2027, and a royalty monetization deal with up to $90 million in potential payments. Investors reviewing the update may focus on how new financials, cash outlook, and clinical progress build on these prior milestones and what management shares about partnered programs and trial timelines.

Key Figures

Upfront royalty payment: $65 million Milestone payment: $25 million Potential milestones: $195 million +5 more

8 metrics

Upfront royalty payment $65 million Rilvegostomig royalty monetization deal, 2025-12-17

Milestone payment $25 million Additional milestone tied to next BLA acceptance

Potential milestones $195 million Total potential regulatory and commercial milestones for partnerships

Q3 2025 cash $86.1M Cash balance with runway into Q3 2027

Q3 2025 revenue $1.9M Compared with $17.1M in prior-year quarter

Q3 2025 net loss $6.98M Loss of $0.07 per share after prior-quarter profit

Median PFS 10.5 months Pooled Phase 1 COM701 patients deriving clinical benefit

Earnings call time 8:30 AM ET Q4 and full-year 2025 results call on March 2, 2026

Historical Context

5 past events · Latest: 2026-02-12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-02-12	Board appointment	Positive	-2.3%	New independent director with extensive biotech and healthcare strategy experience added.
2025-12-17	Royalty monetization	Positive	+2.0%	Non-dilutive monetization of rilvegostomig royalties with upfront and milestone payments.
2025-11-10	Earnings results	Neutral	+3.1%	Q3 2025 financials, cash runway, clinical data and partnership updates reported.
2025-11-04	Conference participation	Neutral	-6.9%	Participation in Stifel 2025 Healthcare Conference with investor webcast access.
2025-10-27	Earnings release announcement	Neutral	-5.0%	Announcement of timing and access details for Q3 2025 results call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often saw price moves in both directions, with conference and earnings-date notices sometimes followed by notable declines.

Recent Company History

Over the last several months, Compugen announced a board appointment on 2026-02-12, a royalty monetization deal with AstraZeneca on 2025-12-17, and Q3 2025 results on 2025-11-10. Earlier, it flagged participation at the Stifel 2025 Healthcare Conference on 2025-11-04 and an earnings-release timing notice on 2025-10-27. These updates mix strategic financing, governance, and clinical/earnings communication, framing the upcoming Q4 and full-year 2025 results within ongoing partnership and pipeline execution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen^™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:

Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2025-results-on-monday-march-2-2026-302689329.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) release Q4 and full year 2025 results and when is the conference call?

Compugen will release Q4 and full year 2025 results on March 2, 2026 before U.S. markets; the conference call is at 8:30 AM ET. According to Compugen, management will review results and provide a corporate update during the live webcast and call.

How can investors join the Compugen (CGEN) earnings call on March 2, 2026?

Investors can join by telephone or live webcast at the scheduled time. According to Compugen, U.S. dial-in is 1-866-744-5399 and international dial-in is +972-3-918-0644, with a webcast available on the company website.

Will Compugen (CGEN) provide a replay of the March 2, 2026 webcast and where is it hosted?

Yes, a replay will be available on the company website after the live webcast. According to Compugen, the replay will be posted on the company’s investor website following the live presentation for later access.

What topics will Compugen (CGEN) management cover during the March 2, 2026 corporate update?

Management will review fourth quarter and full year 2025 financial results and provide a corporate update at the call. According to Compugen, the webcast is intended to discuss results and recent company developments relevant to investors.

What time should international investors log on for Compugen (CGEN) results on March 2, 2026?

International investors should join at 8:30 AM ET, which corresponds to local international dial-in times. According to Compugen, the international phone number is +972-3-918-0644 and the webcast is available globally on the company website.